178 related articles for article (PubMed ID: 34411069)
1. Use of venetoclax combination regimens in chronic lymphocytic leukemia.
Tam CS
Clin Adv Hematol Oncol; 2021 Aug; 19(8):504-506. PubMed ID: 34411069
[No Abstract] [Full Text] [Related]
2. Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia.
Yang L; Banerji V
Lancet Oncol; 2024 Apr; 25(4):413-414. PubMed ID: 38547887
[No Abstract] [Full Text] [Related]
3. Emerging data for venetoclax in chronic lymphocytic leukemia.
O'Brien SM
Clin Adv Hematol Oncol; 2022 Mar; 20(3):178-183. PubMed ID: 36607348
[No Abstract] [Full Text] [Related]
4. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A; Mauro FR; Scarfò L; Gentile M; Farina L; Reda G; Ferrarini I; Proietti G; Derenzini E; Cibien F; Vitale C; Sanna A; Pietrasanta D; Marchetti M; Murru R; Rigolin GM; Sportoletti P; Trimarco V; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Zatta I; Laurenti L; Molica S; Coscia M; Ghia P; Foà R; Cuneo A; Trentin L
Am J Hematol; 2023 Sep; 98(9):E237-E240. PubMed ID: 37382471
[No Abstract] [Full Text] [Related]
5. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
8. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Jiang R; Dai LMJ; Sha YQ; Xia Y; Miao Y; Qin SC; Wu W; Qiu JY; Bi HL; Wang L; Fan L; Xu W; Li JY; Zhu HY
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):247-250. PubMed ID: 37356988
[No Abstract] [Full Text] [Related]
10. Autoimmune hemolytic anemia, adverse event to venetoclax.
Carriles C; Ordóñez-Fernández L; Arias-Martínez A; Menárguez-Blanc R; Rosado-María MC
Farm Hosp; 2019 Sep; 43(5):166-167. PubMed ID: 31469630
[No Abstract] [Full Text] [Related]
11. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
12. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
13. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
14. Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; De Carolis L; Santi A; Falini B
N Engl J Med; 2023 Mar; 388(10):952-954. PubMed ID: 36884329
[No Abstract] [Full Text] [Related]
15. Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Fischer K; Al-Sawaf O; Fink AM; Dixon M; Bahlo J; Warburton S; Kipps TJ; Weinkove R; Robinson S; Seiler T; Opat S; Owen C; López J; Humphrey K; Humerickhouse R; Tausch E; Frenzel L; Eichhorst B; Wendtner CM; Stilgenbauer S; Langerak AW; van Dongen JJM; Böttcher S; Ritgen M; Goede V; Mobasher M; Hallek M
Blood; 2017 May; 129(19):2702-2705. PubMed ID: 28325865
[No Abstract] [Full Text] [Related]
16. GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.
Rogers KA
Lancet Oncol; 2024 Jun; 25(6):685-687. PubMed ID: 38821078
[No Abstract] [Full Text] [Related]
17. Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Hengeveld PJ; Schilperoord-Vermeulen J; van der Klift MY; Dubois JMN; Kolijn PM; Kavelaars FG; Rijken M; Dobber JA; Nasserinejad K; Kersting S; Westerweel PE; Kater AP; Langerak AW; Levin MD
Blood Cancer J; 2023 Jul; 13(1):102. PubMed ID: 37400508
[No Abstract] [Full Text] [Related]
18. Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361-369.
Blood; 2023 Mar; 141(11):1366. PubMed ID: 36929430
[No Abstract] [Full Text] [Related]
19. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Autore F; Visentin A; Deodato M; Vitale C; Galli E; Fresa A; Fazzi R; Sanna A; Olivieri J; Scortechini I; Del Principe MI; Sportoletti P; Schiattone L; Maschio N; Facchinelli D; Marchesi F; Coscia M; Tedeschi A; Trentin L; Innocenti I; Candoni A; Busca A; Pagano L; Laurenti L
Am J Hematol; 2024 May; 99(5):982-984. PubMed ID: 38343033
[No Abstract] [Full Text] [Related]
20. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
Stirrups R
Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
